GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2009

Roche to Use Kinaxo’s Technology to Hunt for Biomarkers Related to Antibodies in Development

  • Roche Diagnostics will use Kinaxo Biotechnologies’ phosphoproteomics technology, PhosphoScout®, to find biomarkers related to antibody-based therapeutics currently under development at Roche. The technology has been developed as a quantitative phosphoproteomic service, which the company says allows the dissection of cellular signal transduction pathways and their response to drug treatment. The platform is based on mass spectrometry methods, enabling the analysis of 15,000 phosphorylation sites in a single experiment. 

    The agreement follows just a week after Kinaxo announced a deal with Bayer Vital, under which PhosphoScout® will be used to identify novel biomarkers associated with drug response in a clinical trial evaluating Nexavar® in acute myeloid leukaemia patients.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?